Hims & Hers Health Shares Plunge 16% to $19.33 on FDA Pill Pull
Hims & Hers Health shares dropped 16.05% to $19.33 after FDA pulled its weight loss pill, a 27.36% slump over the past month. Q4 earnings are due February 23 with consensus EPS $0.04 (-63.6%), revenue $620.4 M (+28.9%) and a forward P/E of 39.7.
1. Stock Plunge on FDA Action
Shares of Hims & Hers Health tumbled 16.05% to close at $19.33 after the FDA pulled its weight loss pill from the market. The move followed mounting regulatory scrutiny and drove a 27.36% decline in the stock over the past month, significantly underperforming the broader market.
2. Upcoming Q4 Earnings Forecast
The company will report fourth-quarter results on February 23 with analysts expecting EPS of $0.04, down 63.6% year-over-year, and revenue of $620.4 million, a 28.9% increase. Investors will watch how pill sales affect top-line growth and whether cost pressures compress margins.
3. Valuation and Analyst Rankings
Hims & Hers Health trades at a forward P/E of 39.7, well above the industry average of 21, and carries a PEG ratio of 3.79 versus 1.57 for peers. Analyst estimate revisions have driven a Zacks Rank of #4 (Sell), reflecting reduced near-term profitability expectations.